血液透析患者产生长效SARS-CoV-2抗体且与再感染减少相关
在990例血液透析患者中,第一波疫情期间26%产生抗SARS-CoV-2刺突蛋白抗体;有抗体者第二波PCR确诊感染率4.2%,无抗体者11.4%。研究表明透析患者SARS-CoV-2抗体维持良好并与后续感染风险降低相关。
要点
- 透析患者感染SARS-CoV-2后抗体维持良好。
- 有抗体者再感染率4.2%,低于无抗体者的11.4%。
- 提示感染诱导抗体可能具有保护作用。
核心结论
- 血液透析患者SARS-CoV-2抗体维持良好并与后续SARS-CoV-2感染风险降低相关。
研究设计与样本
- 队列研究,纳入990例血液透析患者,描述抗SARS-CoV-2刺突蛋白抗体演变。
主要发现
- 第一波疫情期间26%患者产生抗刺突SARS-CoV-2抗体。
- 有抗体者第二波PCR确诊感染率4.2%,无抗体者11.4%。
临床怎么用
- 透析患者感染后抗体可长期维持,可能降低再感染风险。
局限性
- 原文未报告抗体保护效力的阈值或剂量,需谨慎解读观察性关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.
引用
- Banham GD, Godlee A, Faustini SE, et al. Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection. J Am Soc Nephrol. 2021. PMID: 34341181. doi:10.1681/ASN.2021020188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。